Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure

BACKGROUND:While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>40%). Sacubitril/valsartan has been compared with a renin-angiotensin-aldosterone–system inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2020-02, Vol.141 (5), p.352-361
Hauptverfasser:	Solomon, Scott D., Vaduganathan, Muthiah, L. Claggett, Brian, Packer, Milton, Zile, Michael, Swedberg, Karl, Rouleau, Jean, A. Pfeffer, Marc, Desai, Akshay, H. Lund, Lars, Kober, Lars, Anand, Inder, Sweitzer, Nancy, Linssen, Gerard, Merkely, Bela, Luis Arango, Juan, Vinereanu, Dragos, Chen, Chen-Huan, Senni, Michele, Sibulo, Antonio, Boytsov, Sergey, Shi, Victor, Rizkala, Adel, Lefkowitz, Martin, McMurray, John J.V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aminobutyrates - therapeutic use Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiac and Cardiovascular Systems clinical efficacy Drug Combinations Female heart failure Heart Failure - drug therapy Heart Failure - physiopathology Humans Kardiologi Male Medicin och hälsovetenskap Middle Aged sacubitril/valsartan Stroke Volume - drug effects Stroke Volume - physiology Tetrazoles - therapeutic use Treatment Outcome ventricular ejection fraction Ventricular Function, Left - drug effects Ventricular Function, Left - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!